Sign In
27 Jun 2018 11:52
PRESS RELEASE
FOR IMMEDIATE RELEASE
Block listing application
London, UK - 27 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 1,800,000 ordinary shares of £0.01 each (the 'New Ordinary Shares') to be admitted to trading on AIM.
The New Ordinary Shares will be issued from time to time in order to satisfy the exercise of share options granted under the Ergomed plc Share Incentive Plan. It is expected that admission will become effective on 2 July 2018.
When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of £0.01 each in the capital of the Company ('Ordinary Shares').
The Company will notify as required when there are changes to the issued share capital of the Company, and these figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 503 205 |
Stephen Stamp (Chief Executive Officer) | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) | |
James Black (Joint Broker) | |
N+1 Singer | Tel: +44 (0) 20 7496 3000 |
Aubrey Powell (Joint Broker) | |
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 |
Chris Gardner / Mary-Jane Elliott / Ivar Milligan | |
MC Services - for Continental European enquiries | Tel: +49 211 5292 5222 |
Anne Hennecke |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
Follow the stocks
